Heyrman Bert, Meers Stef, Van De Velde Ann, Anguille Sébastien
Ziekenhuis Netwerk Antwerpen, Department of Haematology, 2020 Antwerp, Belgium.
Algemeen Ziekenhuis KLINA, Department of Haematology, 2930 Brasschaat, Belgium.
Clin Pract. 2023 Nov 23;13(6):1520-1531. doi: 10.3390/clinpract13060133.
Despite the motivation of oncology patients to take part in clinical trials, only a minority of them are enrolled in clinical trials. Implementation of new practical procedures can become a barrier that withholds patients from participating in clinical trials. Treating physicians are crucial in augmenting trial accrual. The drivers that promote physicians to allocate patients for clinical trials need further assessment. We conducted two separate cross-sectional surveys, addressing patients with a haematological disease in one survey and haematologists in another survey. The patient survey was filled out by 420 patients. Significant relationships between the willingness to participate in a trial and trial knowledge ( < 0.001) and between doctor-patient relationship and participation willingness ( = 0.007) were noted. Patients above 60 years were less willing to use an electronic consent procedure vs. patients younger than 60 ( < 0.001). The physician questionnaire was completed by 42 participants of whom most (83%) were active in and (94%) motivated for clinical trials. Apart from the patient benefit and scientific interest, prestige was an equal motivator closely followed by financial remunerations. First goal was not to harm the patient. Our study confirms the high willingness of patients for trial participation and the need to rethink the structure of trial organisation. The e-consent procedure is not the method preferred by most patients above 60 years old.
尽管肿瘤患者有参与临床试验的积极性,但只有少数患者参加了临床试验。新的实践程序的实施可能成为阻碍患者参与临床试验的障碍。治疗医生在增加试验入组率方面至关重要。促进医生为临床试验分配患者的驱动因素需要进一步评估。我们进行了两项独立的横断面调查,一项针对血液系统疾病患者,另一项针对血液科医生。420名患者填写了患者调查问卷。结果发现,参与试验的意愿与试验知识之间存在显著关系(<0.001),医患关系与参与意愿之间也存在显著关系(=0.007)。60岁以上的患者比60岁以下的患者更不愿意使用电子同意程序(<0.001)。42名参与者完成了医生调查问卷,其中大多数(83%)积极参与临床试验且(94%)有参与积极性。除了患者受益和科学兴趣外,声誉是一个同样重要的激励因素,紧随其后的是经济报酬。首要目标是不伤害患者。我们的研究证实了患者参与试验的高度意愿以及重新思考试验组织架构的必要性。电子同意程序并非大多数60岁以上患者首选的方法。